{"id":"thalidomide-cyclophosphamide-dexamethasone","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Thalidomide's mechanism of action involves the inhibition of TNF-alpha production, which is a pro-inflammatory cytokine involved in the pathogenesis of multiple myeloma. Cyclophosphamide works by cross-linking DNA strands, thereby interfering with DNA replication and leading to cell death. Dexamethasone, on the other hand, exerts its effects by suppressing inflammation and immune response, which is beneficial in reducing the symptoms associated with multiple myeloma.","oneSentence":"Thalidomide is a glutamic acid derivative that inhibits tumor necrosis factor-alpha (TNF-alpha) production, while Cyclophosphamide is an alkylating agent that interferes with DNA replication, and Dexamethasone is a corticosteroid that suppresses inflammation and immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:21.983Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT02844309","phase":"PHASE4","title":"The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-05","conditions":"Waldenström Macroglobulinemia","enrollment":44},{"nctId":"NCT02858804","phase":"PHASE4","title":"EDOCH Alternating With DHAP for New Diagnosed Younger MCL","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-01","conditions":"Mantle Cell Lymphoma","enrollment":55},{"nctId":"NCT00572169","phase":"PHASE3","title":"UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2006-11","conditions":"Multiple Myeloma","enrollment":177},{"nctId":"NCT02461888","phase":"PHASE2","title":"Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2015-12","conditions":"Multiple Myeloma","enrollment":112},{"nctId":"NCT03004287","phase":"PHASE2","title":"2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2017-07-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT01659658","phase":"PHASE3","title":"Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis","status":"TERMINATED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2012-12-26","conditions":"Relapsed or Refractory Systemic Light Chain Amyloidosis","enrollment":177},{"nctId":"NCT03896737","phase":"PHASE2","title":"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2019-04-16","conditions":"Multiple Myeloma","enrollment":401},{"nctId":"NCT00871013","phase":"PHASE2","title":"Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2009-03","conditions":"Myeloma","enrollment":160},{"nctId":"NCT00869232","phase":"PHASE2","title":"UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-10","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT00734877","phase":"PHASE3","title":"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-07","conditions":"Multiple Myeloma","enrollment":382},{"nctId":"NCT01539083","phase":"PHASE3","title":"Velcade (Bortezomib) Consolidation After Transplant","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2012-01-13","conditions":"Multiple Myeloma","enrollment":256},{"nctId":"NCT06457464","phase":"","title":"Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-07-01","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT02586038","phase":"PHASE2","title":"STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS","status":"COMPLETED","sponsor":"Mario Boccadoro","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":175},{"nctId":"NCT03759093","phase":"PHASE2, PHASE3","title":"CURATE.AI Optimized Modulation for Multiple Myeloma","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2023-09-10","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT01849783","phase":"PHASE2","title":"Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Margarida Magalhaes-Silverman","startDate":"2013-04-04","conditions":"Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease","enrollment":41},{"nctId":"NCT02128230","phase":"PHASE2","title":"UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2014-06-10","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT04120519","phase":"PHASE2","title":"Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-10-10","conditions":"Langerhans Cell Histiocytosis","enrollment":20},{"nctId":"NCT03792620","phase":"PHASE3","title":"Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation","status":"UNKNOWN","sponsor":"Grupo de Estudos Multicentricos em Onco-Hematologia","startDate":"2018-11-20","conditions":"Multiple Myeloma Stage I","enrollment":20},{"nctId":"NCT00064337","phase":"PHASE2","title":"S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2004-01","conditions":"Multiple Myeloma, Plasma Cell Myeloma","enrollment":104},{"nctId":"NCT01554852","phase":"PHASE3","title":"Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2010-05","conditions":"Multiple Myeloma","enrollment":4420},{"nctId":"NCT02559154","phase":"PHASE4","title":"Modified Bortezomib-based Combination Therapy for Multiple Myeloma","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2010-07","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT03402295","phase":"PHASE3","title":"Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation","status":"COMPLETED","sponsor":"Grupo de Estudos Multicentricos em Onco-Hematologia","startDate":"2009-06-15","conditions":"Multiple Myeloma, Effects of Chemotherapy","enrollment":311},{"nctId":"NCT01057225","phase":"PHASE1, PHASE2","title":"Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2010-03","conditions":"Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma","enrollment":64},{"nctId":"NCT00577512","phase":"PHASE2","title":"2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2007-04","conditions":"Multiple Myeloma","enrollment":4},{"nctId":"NCT00083915","phase":"PHASE3","title":"DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2001-06","conditions":"Multiple Myeloma","enrollment":97},{"nctId":"NCT00574080","phase":"PHASE3","title":"UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2006-07","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT00113919","phase":"PHASE1, PHASE2","title":"UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2004-06","conditions":"Multiple Myeloma","enrollment":14},{"nctId":"NCT02248428","phase":"PHASE3","title":"Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma","status":"UNKNOWN","sponsor":"Jinling Hospital, China","startDate":"2012-04","conditions":"Multiple Myeloma","enrollment":130},{"nctId":"NCT00670631","phase":"PHASE2","title":"Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment","status":"COMPLETED","sponsor":"Guido Tricot","startDate":"2008-02","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT01548573","phase":"PHASE2","title":"Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment","status":"TERMINATED","sponsor":"University of Iowa","startDate":"2012-05","conditions":"Multiple Myeloma","enrollment":19},{"nctId":"NCT01632150","phase":"PHASE2","title":"Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":51},{"nctId":"NCT00040937","phase":"PHASE2","title":"S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2002-06","conditions":"Multiple Myeloma","enrollment":147},{"nctId":"NCT00083551","phase":"PHASE3","title":"UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"1998-08","conditions":"Multiple Myeloma","enrollment":668},{"nctId":"NCT00450801","phase":"PHASE2","title":"R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2004-04","conditions":"Lymphoma","enrollment":22},{"nctId":"NCT01971658","phase":"PHASE3","title":"Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2013-10","conditions":"Multiple Myeloma","enrollment":358},{"nctId":"NCT00577096","phase":"NA","title":"Effects of Exercise in Combination With Epoetin Alfa","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2001-10","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT00723658","phase":"PHASE2","title":"S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2008-09","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT01055301","phase":"PHASE2","title":"S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2011-07","conditions":"Multiple Myeloma, Plasma Cell Myeloma","enrollment":""},{"nctId":"NCT00005834","phase":"PHASE3","title":"S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2000-04","conditions":"Multiple Myeloma","enrollment":19},{"nctId":"NCT00934739","phase":"PHASE2, PHASE3","title":"A Study of High-Risk Oral Cavity Cancer","status":"TERMINATED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2007-06","conditions":"Oral Cavity Cancer","enrollment":150},{"nctId":"NCT01537861","phase":"EARLY_PHASE1","title":"Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2012-06","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT00028886","phase":"PHASE3","title":"Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma","status":"UNKNOWN","sponsor":"Commissie Voor Klinisch Toegepast Onderzoek","startDate":"2001-03","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":450},{"nctId":"NCT01134484","phase":"PHASE3","title":"VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)","status":"UNKNOWN","sponsor":"Michele Cavo","startDate":"2006-05","conditions":"Multiple Myeloma","enrollment":480},{"nctId":"NCT00089453","phase":"PHASE1","title":"Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2003-09","conditions":"Multiple Myeloma","enrollment":10},{"nctId":"NCT01532856","phase":"PHASE3","title":"Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years","status":"UNKNOWN","sponsor":"Grupo de Estudos Multicentricos em Onco-Hematologia","startDate":"2007-01","conditions":"Multiple Myeloma","enrollment":64},{"nctId":"NCT00531453","phase":"PHASE2","title":"A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2007-10","conditions":"Multiple Myeloma","enrollment":98},{"nctId":"NCT01114048","phase":"PHASE2","title":"Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)","status":"UNKNOWN","sponsor":"Chonnam National University Hospital","startDate":"2010-03","conditions":"Multiple Myeloma","enrollment":78},{"nctId":"NCT00652041","phase":"PHASE4","title":"Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2007-01","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT00113932","phase":"PHASE2","title":"UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2003-12","conditions":"Multiple Myeloma","enrollment":140},{"nctId":"NCT01341262","phase":"PHASE2","title":"THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2002-03","conditions":"Multiple Myeloma","enrollment":378},{"nctId":"NCT00083538","phase":"PHASE2","title":"Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2001-02","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT00083876","phase":"PHASE3","title":"D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"1998-09","conditions":"Multiple Myeloma","enrollment":500},{"nctId":"NCT00083681","phase":"PHASE2","title":"DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"1998-06","conditions":"Multiple Myeloma","enrollment":180},{"nctId":"NCT01070862","phase":"PHASE3","title":"Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2003-05","conditions":"Multiple Myeloma de Novo Treatment","enrollment":""},{"nctId":"NCT00124813","phase":"PHASE2","title":"Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma","status":"UNKNOWN","sponsor":"University Hospital, Bonn","startDate":"2002-08","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT00461747","phase":"PHASE3","title":"GEM05 for Patients With Multiple Myeloma Under 65 Years","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-03","conditions":"Multiple Myeloma","enrollment":390},{"nctId":"NCT00438841","phase":"PHASE2","title":"Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma","status":"UNKNOWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-08","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":43},{"nctId":"NCT00349115","phase":"PHASE2","title":"TCD Followed by autoSCT for Newly Diagnosed MM Patients","status":"UNKNOWN","sponsor":"Korean Multiple Myeloma Working Party","startDate":"2006-06","conditions":"Multiple Myeloma","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Thalidomide, Cyclophosphamide, Dexamethasone","genericName":"Thalidomide, Cyclophosphamide, Dexamethasone","companyName":"Grupo de Estudos Multicentricos em Onco-Hematologia","companyId":"grupo-de-estudos-multicentricos-em-onco-hematologia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Thalidomide, Cyclophosphamide, and Dexamethasone are small molecule drugs used in the treatment of Multiple Myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}